4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Portfolio Pulse from
The article highlights four biotech stocks - SRPT, ADMA, EXEL, and ALNY - that Wall Street analysts are optimistic about, citing strong fundamentals and potential upside by 2025.
December 19, 2024 | 7:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADMA Biologics (ADMA) is among the biotech stocks favored by analysts, with strong fundamentals and potential upside by 2025.
ADMA is mentioned as a stock with strong fundamentals and potential upside, suggesting a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Alnylam Pharmaceuticals (ALNY) is one of the biotech stocks analysts are bullish about, with strong fundamentals and potential upside by 2025.
ALNY is highlighted for its strong fundamentals and potential upside, indicating a likely positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Exelixis (EXEL) is identified as a biotech stock with strong fundamentals and potential upside by 2025, according to analysts.
EXEL is noted for its strong fundamentals and potential upside, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sarepta Therapeutics (SRPT) is one of the biotech stocks that analysts are optimistic about, with strong fundamentals and potential upside by 2025.
SRPT is highlighted as a stock with strong fundamentals and potential upside, which is likely to positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80